Back to Search Start Over

Validation of Noninvasive Markers for HCC Risk Stratification in 1389 Patients With Biopsy-proven NAFLD

Authors :
Hidenori Toyoda
Hideki Fujii
Michihiro Iwaki
Hideki Hayashi
Satoshi Oeda
Hideyuki Hyogo
Miwa Kawanaka
Asahiro Morishita
Kensuke Munekage
Kazuhito Kawata
Sakura Yamamura
Koji Sawada
Tatsuji Maeshiro
Hiroshi Tobita
Yuichi Yoshida
Masafumi Naito
Asuka Araki
Shingo Arakaki
Takumi Kawaguchi
Hidenao Noritake
Masafumi Ono
Tsutomu Masaki
Satoshi Yasuda
Eiichi Tomita
Masato Yoneda
Norifumi Kawada
Akihiro Tokushige
Yoshihiro Kamada
Hirokazu Takahashi
Shinichiro Ueda
Shinichi Aishima
Yoshio Sumida
Atsushi Nakajima
Takeshi Okanoue
Source :
Gastro Hep Advances, Vol 2, Iss 8, Pp 1093-1102 (2023)
Publication Year :
2023
Publisher :
Elsevier, 2023.

Abstract

Background and Aims: Nonalcoholic fatty liver diseases (NAFLD) and nonalcoholic steatohepatitis (NASH) can cause hepatocellular carcinoma (HCC). We examined histological features and reported noninvasive markers/models for stratifying the risk of HCC development in patients with biopsy-proven NAFLD or NASH. Methods: A total of 1389 patients who had a histological diagnosis of NAFLD or NASH based on liver biopsy and underwent regular surveillance for HCC were included. The ability to predict HCC development was compared between histological features including liver fibrosis and NAFLD activity score, and noninvasive markers/models including aMAP (age, male, albumin–bilirubin, and platelet) score, FIB-4 (Fibrosis-4) index, and ALBI (albumin-bilirubin) score calculated at the time of biopsy. Results: The C index of aMAP score was 0.887, which was consistent with the original report, comparable to FIB-4 index (0.878), and higher than those of ALBI score (0.789), histological liver fibrosis (0.723), and NAFLD activity score (0.589). The hazard ratios for HCC development in the aMAP intermediate and high-risk groups were 21.0 (95% confidence interval [CI], 3.6–402.0) and 110.3 (95% CI, 16.3–2251.4), respectively, in comparison to the aMAP score low-risk group. Those in the FIB-4 index moderate- and high-fibrosis groups were 10.3 (95% CI, 1.7–199.8) and 93.1 (95% CI, 16.3–1773.8), respectively, in comparison to the FIB-4 index mild-fibrosis group. No patients in the aMAP score low-risk group developed HCC during the study period. Conclusion: For stratifying the risk of HCC development in patients with biopsy-proven NAFLD or NASH, both aMAP score and FIB-4 index showed high discriminative ability as noninvasive markers, which were superior histological features.

Details

Language :
English
ISSN :
27725723
Volume :
2
Issue :
8
Database :
Directory of Open Access Journals
Journal :
Gastro Hep Advances
Publication Type :
Academic Journal
Accession number :
edsdoj.565057de6be7408291dbc2b4ff90b031
Document Type :
article
Full Text :
https://doi.org/10.1016/j.gastha.2023.07.018